HEMOLUNG® Publications – ALung Technologies, Inc.

ALung believes peer-reviewed literature is an important part of educating the clinical community about new technologies such ECCO₂R. The following table of publications is intended as an educational tool to aid in clinician understanding of ECCO₂R and HEMOLUNG therapy.

The HEMOLUNG must be used in accordance with the approved indication for use.

Indication for Use: The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO₂) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO₂ cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.

Select HEMOLUNG Publications
Avoid Intubation	A Retrospective Observational Case Series of Low-Flow Venovenous ECCO2R Use in Patients with Respiratory Failure
	Early Experience of a New Extracorporeal Carbon Dioxide Removal Device for Acute Hypercapnic Respiratory Failure
	Use of Extracorporeal CO2 Removal to Avoid Invasive Mechanical Ventilation in Hypercapnic Coma and Failure of Noninvasive Ventilation
	Extracorporeal Carbon Dioxide Removal as an Alternative to Endotracheal Intubation for Noninvasive Ventilation Failure in Acute Exacerbation of COPD
	Respiratory Dialysis for Avoidance of Intubation in Acute Exacerbation of COPD
	A Novel Extracorporeal CO2 Removal System: Results of a Pilot Study of Hypercapnic Respiratory Failure in Patients with COPD
De-Escalate Mechanical Ventilation Settings Correct Hypercapnia and Respiratory Acidosis	Early Experience of a New Extracorporeal Carbon Dioxide Removal Device for Acute Hypercapnic Respiratory Failure
	A Retrospective Observational Case Series of Low-Flow Venovenous Extracorporeal Carbon Dioxide Removal Use in Patients with Respiratory Failure
	Low-flow Extracorporeal Carbon Dioxide Removal Using the Hemolung Respiratory Dialysis System® to Facilitate Lung-Protective Mechanical Ventilation in Acute Respiratory Distress Syndrome
	Early Experience of a New Extracorporeal Carbon Dioxide Removal Device for Acute Hypercapnic Respiratory Failure
	Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System
	Physiologic Improvement in Respiratory Acidosis Using Extracorporeal CO2 Removal With Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure From Coronavirus Disease 2019
	Extracorporeal CO2 reduction for COVID-19: hypercapnic respiratory failure post extracorporeal membrane oxygenation
	A randomised controlled trial of non-invasive ventilation compared with extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease

ADDITIONAL INFORMATION

Summary of HEMOLUNG® Publications 2022